Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer ; 123(19): 3807-3815, 2017 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-28608950

RESUMO

BACKGROUND: Programmed death 1 (PD-1) signaling in the tumor microenvironment dampens immune responses to cancer, and blocking this axis induces antitumor effects in several malignancies. Clinical studies of PD-1 blockade are only now being initiated in pediatric patients, and little is known regarding programmed death-ligand 1 (PD-L1) expression in common childhood cancers. The authors characterized PD-L1 expression and tumor-associated immune cells (TAICs) (lymphocytes and macrophages) in common pediatric cancers. METHODS: Whole slide sections and tissue microarrays were evaluated by immunohistochemistry for PD-L1 expression and for the presence of TAICs. TAICs were also screened for PD-L1 expression. RESULTS: Thirty-nine of 451 evaluable tumors (9%) expressed PD-L1 in at least 1% of tumor cells. The highest frequency histotypes comprised Burkitt lymphoma (80%; 8 of 10 tumors), glioblastoma multiforme (36%; 5 of 14 tumors), and neuroblastoma (14%; 17 of 118 tumors). PD-L1 staining was associated with inferior survival among patients with neuroblastoma (P = .004). Seventy-four percent of tumors contained lymphocytes and/or macrophages. Macrophages were significantly more likely to be identified in PD-L1-positive versus PD-L1-negative tumors (P < .001). CONCLUSIONS: A subset of diagnostic pediatric cancers exhibit PD-L1 expression, whereas a much larger fraction demonstrates infiltration with tumor-associated lymphocytes. PD-L1 expression may be a biomarker for poor outcome in neuroblastoma. Further preclinical and clinical investigation will define the predictive nature of PD-L1 expression in childhood cancers both at diagnosis and after exposure to chemoradiotherapy. Cancer 2017;123:3807-3815. © 2017 American Cancer Society.


Assuntos
Antígeno B7-H1/análise , Linfócitos do Interstício Tumoral , Macrófagos , Proteínas de Neoplasias/análise , Neoplasias/química , Neoplasias Ósseas/química , Neoplasias Ósseas/imunologia , Neoplasias Ósseas/mortalidade , Neoplasias Ósseas/patologia , Linfoma de Burkitt/química , Linfoma de Burkitt/imunologia , Linfoma de Burkitt/patologia , Criança , Glioblastoma/química , Glioblastoma/imunologia , Glioblastoma/patologia , Humanos , Imuno-Histoquímica , Neoplasias/imunologia , Neoplasias/mortalidade , Neoplasias/patologia , Neuroblastoma/química , Neuroblastoma/imunologia , Neuroblastoma/mortalidade , Neuroblastoma/patologia , Osteossarcoma/química , Osteossarcoma/imunologia , Osteossarcoma/patologia , Rabdomiossarcoma/química , Rabdomiossarcoma/imunologia , Rabdomiossarcoma/patologia , Sarcoma de Ewing/química , Sarcoma de Ewing/imunologia , Sarcoma de Ewing/patologia , Análise Serial de Tecidos
2.
Clin Cancer Res ; 22(22): 5461-5471, 2016 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-27169994

RESUMO

PURPOSE: Nivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival versus everolimus in a phase 3 trial of previously treated patients with metastatic renal cell carcinoma (mRCC). We investigated immunomodulatory activity of nivolumab in a hypothesis-generating prospective mRCC trial. EXPERIMENTAL DESIGN: Nivolumab was administered intravenously every 3 weeks at 0.3, 2, or 10 mg/kg to previously treated patients and 10 mg/kg to treatment-naïve patients with mRCC. Baseline and on-treatment biopsies and blood were obtained. Clinical activity, tumor-associated lymphocytes, PD-L1 expression (Dako immunohistochemistry; ≥5% vs. <5% tumor membrane staining), tumor gene expression (Affymetrix U219), serum chemokines, and safety were assessed. RESULTS: In 91 treated patients, median overall survival [95% confidence interval (CI)] was 16.4 months [10.1 to not reached (NR)] for nivolumab 0.3 mg/kg, NR for 2 mg/kg, 25.2 months (12.0 to NR) for 10 mg/kg, and NR for treatment-naïve patients. Median percent change from baseline in tumor-associated lymphocytes was 69% (CD3+), 180% (CD4+), and 117% (CD8+). Of 56 baseline biopsies, 32% had ≥5% PD-L1 expression, and there was no consistent change from baseline to on-treatment biopsies. Transcriptional changes in tumors on treatment included upregulation of IFNγ-stimulated genes (e.g., CXCL9). Median increases in chemokine levels from baseline to C2D8 were 101% (CXCL9) and 37% (CXCL10) in peripheral blood. No new safety signals were identified. CONCLUSIONS: Immunomodulatory effects of PD-1 inhibition were demonstrated through multiple lines of evidence across nivolumab doses. Biomarker changes from baseline reflect nivolumab pharmacodynamics in the tumor microenvironment. These data may inform potential combinations. Clin Cancer Res; 22(22); 5461-71. ©2016 AACR.


Assuntos
Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais/uso terapêutico , Carcinoma de Células Renais/imunologia , Carcinoma de Células Renais/terapia , Fatores Imunológicos/imunologia , Fatores Imunológicos/uso terapêutico , Neoplasias Renais/imunologia , Neoplasias Renais/terapia , Antineoplásicos/imunologia , Antineoplásicos/uso terapêutico , Antígeno B7-H1/imunologia , Quimiocina CXCL10/imunologia , Quimiocina CXCL9/imunologia , Everolimo/imunologia , Everolimo/uso terapêutico , Feminino , Humanos , Interferon gama/imunologia , Linfócitos/efeitos dos fármacos , Linfócitos/imunologia , Masculino , Pessoa de Meia-Idade , Nivolumabe , Estudos Prospectivos , Microambiente Tumoral/efeitos dos fármacos , Microambiente Tumoral/imunologia , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/imunologia
3.
N Engl J Med ; 373(19): 1803-13, 2015 Nov 05.
Artigo em Inglês | MEDLINE | ID: mdl-26406148

RESUMO

BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). CONCLUSIONS: Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).


Assuntos
Anticorpos Monoclonais/uso terapêutico , Antineoplásicos/uso terapêutico , Carcinoma de Células Renais/tratamento farmacológico , Neoplasias Renais/tratamento farmacológico , Sirolimo/análogos & derivados , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticorpos Monoclonais/efeitos adversos , Antineoplásicos/efeitos adversos , Carcinoma de Células Renais/mortalidade , Everolimo , Feminino , Humanos , Neoplasias Renais/mortalidade , Masculino , Pessoa de Meia-Idade , Nivolumabe , Qualidade de Vida , Sirolimo/efeitos adversos , Sirolimo/uso terapêutico , Análise de Sobrevida , Adulto Jovem
4.
J Lipid Res ; 51(5): 1201-7, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-19752398

RESUMO

Niemann-Pick C1-like 1 protein (NPC1L1) plays a critical role in intestinal cholesterol absorption. Our objective was to examine whether five variants (-133A>G, -18A>C, L272L, V1296V, and U3_28650A>G) at the NPC1L1 gene have effects on lipid levels, prevalence, and incidence of coronary heart disease (CHD) and lipid-lowering response to pravastatin. We studied 5,804 elderly participants from the PROSPER study, who were randomized to prava-statin 40 mg/day or placebo and were followed on average for 3.2 years. In the adjusted gender-pooled analyses, homozygous carriers of the minor alleles at four NPC1L1 sites (-18A>C, L272L, V1296V, and U3_28650A>G, minor allele frequencies 0.15-0.33) had 2-8% higher LDL-cholesterol (LDL-C) levels at baseline than homozygous carriers of the common alleles (P < 0.05). Homozygotes for the rare alleles also had a significant increase in the risk of CHD events on trial (range of hazard ratios 1.50-1.67; P < 0.02), regardless of the treatment regimen. The -133 A>G polymorphism and not other variants was associated with 6 month LDL-C lowering (P = 0.02). Our data indicate that variation in the NPC1L1 gene is associated with plasma total and LDL-C levels and CHD risk.


Assuntos
Doença das Coronárias/sangue , Doença das Coronárias/genética , Loci Gênicos/genética , Predisposição Genética para Doença , Variação Genética , Lipoproteínas/sangue , Proteínas de Membrana/genética , Idoso , Idoso de 80 Anos ou mais , Doença das Coronárias/tratamento farmacológico , Doença das Coronárias/epidemiologia , Feminino , Humanos , Masculino , Proteínas de Membrana Transportadoras , Polimorfismo de Nucleotídeo Único , Pravastatina/uso terapêutico , Risco , Resultado do Tratamento
5.
Nature ; 461(7262): 399-401, 2009 Sep 17.
Artigo em Inglês | MEDLINE | ID: mdl-19684573

RESUMO

Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America. Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-alpha-2b (PegIFN-alpha-2b) or -alpha-2a (PegIFN-alpha-2a) combined with ribavirin (RBV), it is well known that many patients will not be cured by treatment, and that patients of European ancestry have a significantly higher probability of being cured than patients of African ancestry. In addition to limited efficacy, treatment is often poorly tolerated because of side effects that prevent some patients from completing therapy. For these reasons, identification of the determinants of response to treatment is a high priority. Here we report that a genetic polymorphism near the IL28B gene, encoding interferon-lambda-3 (IFN-lambda-3), is associated with an approximately twofold change in response to treatment, both among patients of European ancestry (P = 1.06 x 10(-25)) and African-Americans (P = 2.06 x 10(-3)). Because the genotype leading to better response is in substantially greater frequency in European than African populations, this genetic polymorphism also explains approximately half of the difference in response rates between African-Americans and patients of European ancestry.


Assuntos
Variação Genética/genética , Hepacivirus/efeitos dos fármacos , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/genética , Interferon-alfa/farmacologia , Interleucinas/genética , Polietilenoglicóis/farmacologia , Carga Viral , Negro ou Afro-Americano/genética , Cromossomos Humanos Par 19/genética , Ensaios Clínicos como Assunto , Europa (Continente)/etnologia , Ásia Oriental/etnologia , Frequência do Gene , Genoma Humano/genética , Estudo de Associação Genômica Ampla , Genótipo , Hepatite C Crônica/etnologia , Hepatite C Crônica/virologia , Hispânico ou Latino/genética , Humanos , Interferon alfa-2 , Interferon-alfa/efeitos adversos , Interferon-alfa/uso terapêutico , Interferons , Farmacogenética , Polietilenoglicóis/efeitos adversos , Polietilenoglicóis/uso terapêutico , Polimorfismo de Nucleotídeo Único/genética , Proteínas Recombinantes
6.
Biochem Pharmacol ; 77(7): 1246-53, 2009 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-19146831

RESUMO

mGluR1 receptors are believed to play major roles in the pathophysiology of diseases such as anxiety and chronic pain and are being actively investigated as targets for drug development. Sequence polymorphisms can potentially influence the efficacy of drugs in patient populations and are therefore an important consideration in the drug development process. To identify DNA sequence variants of the mGluR1 receptor, comparative DNA sequencing was performed on DNA samples (n=186) from apparently healthy subjects representing two ethnic groups. In total, eight non-synonymous single nucleotide polymorphisms (SNPs) were identified and one SNP (c2977>T) was found to be particularly common, this SNP results in a proline to serine substitution at residue 993 (P993S). The WT (P993) and S993 variants were expressed in an inducible system which allowed us to titrate gene expression to equivalent levels and were pharmacologically characterized. We determined the potency and affinity of standard antagonist compounds as well as the potency and efficacy of the endogenous ligand glutamate and other agonist compounds at both receptor variants. Agonist evoked increases in intracellular Ca(2+) were measured by fluorometric imaging plate reader (FLIPR). The potency of mGluR1 antagonists was evaluated by their ability to inhibit quisqualate induced increases in intracellular Ca(2+), while their affinities were determined by radio-ligand binding studies. This study demonstrates that the Pro993Ser amino acid exchange is highly frequent in the human mGluR1 gene. This polymorphism however, does not appear to affect the potency of agonist compounds or the potencies or affinities of small molecule antagonist compounds.


Assuntos
Substituição de Aminoácidos/genética , Antagonistas de Aminoácidos Excitatórios/farmacologia , Variação Genética/genética , Ácido Glutâmico/farmacologia , Polimorfismo de Nucleotídeo Único/genética , Receptores de Glutamato Metabotrópico/genética , Linhagem Celular , Ácido Glutâmico/análogos & derivados , Humanos , Ligação Proteica/efeitos dos fármacos , Ligação Proteica/genética , Receptores de Glutamato Metabotrópico/agonistas , Receptores de Glutamato Metabotrópico/antagonistas & inibidores
7.
Genomics ; 90(5): 629-35, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17869477

RESUMO

Mice lacking GPR103A expression display osteopenia. Analysis of mouse quantitative trait loci literature associated with bone mineral density suggested GPR103A ligand P518/Qrfp (chromosome 2qB) as a candidate osteoporosis gene. Promoter and coding regions of mouse P518/Qrfp were sequenced from genomic DNA obtained from the osteoporosis-prone strain SAMP6 and control strains SAMR1, A/J, AKR/J, BALB/c, C3H/HeJ, C57BL/6J, and DBA/2J. Four single-nucleotide polymorphisms (SNPs) were identified in only SAMP6 genomic DNA, g.-1773 T-->C, g.110 A-->G (N37S), g.188 G-->A (R63K), and g.135 T-->C (H45H). The promoter SNP generated a novel neuron-restrictive silencing factor binding site, a repressor that decreases gene expression in nonneuronal tissues. TaqMan analysis demonstrated fivefold lower P518/Qrfp liver expression in SAMP6 versus SAMR1 or C57BL/6J control strains. Tissue distribution of human, mouse, and rat P518/Qrfp and its receptors showed expression in bone and spinal cord. A direct role for P518/Qrfp function in maintaining bone mineral density is suggested.


Assuntos
Doenças Ósseas Metabólicas/genética , Fases de Leitura Aberta/genética , Peptídeos/genética , Polimorfismo de Nucleotídeo Único/genética , Regiões Promotoras Genéticas/genética , Característica Quantitativa Herdável , Receptores Acoplados a Proteínas G/genética , Sequência de Aminoácidos , Animais , Densidade Óssea , Humanos , Peptídeos e Proteínas de Sinalização Intercelular , Ligantes , Camundongos , Camundongos Endogâmicos , Dados de Sequência Molecular , Ratos , Homologia de Sequência de Aminoácidos , Distribuição Tecidual
8.
Arch Dermatol Res ; 299(7): 305-13, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17647003

RESUMO

Several reports have indicated that the chemokine receptor CCR5 and its ligands, especially CCL5 (formerly known as RANTES), may play a role in the pathogenesis of psoriasis. The purpose of this investigation was to examine the expression of CCR5 and its ligands in chronic plaque psoriasis and to evaluate the clinical and immunohistochemical effect of a CCR5 receptor inhibitor. Immunohistochemical analysis showed low but significant increased total numbers of CCR5 positive cells in epidermis and dermis of lesional skin in comparison to non-lesional skin. However, relative expression of CCR5 proportional to the cells observed revealed that the difference between lesional and non-lesional skin was only statistically significant in the epidermis for CD3 positive cells and in the dermis for CD68 positive cells. Quantification of mRNA by reverse transcriptase-polymerase chain reaction only showed an increased expression of CCL5 (RANTES) in lesional skin. A randomized placebo-controlled clinical trial in 32 psoriasis patients revealed no significant clinical effect and no changes at the immunohistochemical level comparing patients treated with placebo or a CCR5 inhibitor SCH351125. We conclude that although CCR5 expression is increased in psoriatic lesions, this receptor does not play a crucial role in the pathogenesis of psoriasis.


Assuntos
Antagonistas dos Receptores CCR5 , Óxidos N-Cíclicos/uso terapêutico , Piperidinas/uso terapêutico , Psoríase/tratamento farmacológico , Piridinas/uso terapêutico , Adulto , Idoso , Método Duplo-Cego , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Oximas , Receptores CCR5/análise , Receptores CCR5/genética , Receptores CCR5/fisiologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Pele/química
9.
Am J Med Genet B Neuropsychiatr Genet ; 144B(7): 869-76, 2007 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-17503474

RESUMO

Cytogenetic imbalances are increasingly being realized as causes of autism. Here, we report a de novo translocation between the short arms of chromosomes 15 and 16 in a female with autism, epilepsy, and global developmental delay. FISH analysis identified a cryptic deletion of approximately 160 kb at the boundary of the first exon and first intron of the 1.7 Mb ataxin-2 binding protein-1 (A2BP1) gene, also called FOX1. Quantitative real time PCR (Q-PCR) analysis verified a deletion of exon 1 in the 5' promoter region of the A2BP1 gene. Reverse transcription PCR (qRT-PCR) showed reduced mRNA expression in the individual's lymphocytes, demonstrating the functional consequence of the deletion. A2BP1 codes for a brain-expressed RNA binding or splicing factor. Because of emerging evidence in the role of RNA processing and gene regulation in pervasive developmental disorders, we performed further screening of A2BP1 in additional individuals with autism from the Autism Genetics Resource Exchange (AGRE) collection. Twenty-seven SNPs were genotyped across A2BP1 in 206 parent-child trios and two regions showed association at P < or = 0.008 level. No additional deletions or clear mutations were identified in 88 probands by re-sequencing of all exons and surrounding intronic regions or quantitative PCR (Q-PCR) of exon 1. Although only nominal association was observed, and no obvious causal mutations were identified, these results suggest that A2BP1 may affect susceptibility or cause autism in a subset of patients. Further investigations in a larger sample may provide additional information regarding the involvement of this gene in the autistic phenotype.


Assuntos
Transtorno Autístico/genética , Proteínas de Ligação a RNA/genética , Pré-Escolar , Cromossomos Humanos Par 15 , Cromossomos Humanos Par 7 , Análise Citogenética , Epilepsia/genética , Feminino , Predisposição Genética para Doença , Genótipo , Humanos , Hibridização in Situ Fluorescente , Deficiência Intelectual/genética , Reação em Cadeia da Polimerase , Polimorfismo de Nucleotídeo Único , Isoformas de Proteínas/genética , Fatores de Processamento de RNA , Translocação Genética
10.
Genomics ; 86(6): 648-56, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16297596

RESUMO

Niemann-Pick C1-like 1 (NPC1L1) is an intestinal cholesterol transporter and the molecular target of ezetimibe, a cholesterol absorption inhibitor demonstrated to reduce LDL-cholesterol (LDL-C) both as monotherapy and when co-administered with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). Interestingly, significant interindividual variability has been observed for rates of intestinal cholesterol absorption and LDL-C reductions at both baseline and post ezetimibe treatment. To test the hypothesis that genetic variation in NPC1L1 could influence the LDL-C response to ezetimibe, we performed extensive resequencing of the gene in 375 apparently healthy individuals and genotyped hypercholesterolemic patients from clinical trial cohorts. No association was observed between NPC1L1 single-nucleotide polymorphism and baseline cholesterol. However, significant associations to LDL-C response to treatment with ezetimibe were observed in patients treated with ezetimibe in two large clinical trials. Our data demonstrate that DNA sequence variants in NPC1L1 are associated with an improvement in response to ezetimibe pharmacotherapy and suggest that detailed analysis of genetic variability in clinical trial cohorts can lead to improved understanding of factors contributing to variable drug response.


Assuntos
Anticolesterolemiantes/farmacologia , Azetidinas/farmacologia , LDL-Colesterol/metabolismo , Variação Genética , Proteínas de Membrana/genética , Negro ou Afro-Americano/genética , Ezetimiba , Frequência do Gene , Hispânico ou Latino/genética , Humanos , Absorção Intestinal/efeitos dos fármacos , Proteínas de Membrana/metabolismo , Proteínas de Membrana Transportadoras , Fitosteróis/sangue , Polimorfismo de Nucleotídeo Único , Análise de Sequência de DNA , Estados Unidos , População Branca/genética
11.
Obes Res ; 12(8): 1327-34, 2004 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-15340116

RESUMO

OBJECTIVE: To identify and functionally characterize single-nucleotide polymorphisms (SNPs) in melanin-concentrating hormone (MCH)-R1 and -R2. RESEARCH METHODS AND PROCEDURES: The entire coding regions and intron/exon splice junction regions of MCH-R1 and MCH-R2 were sequenced from anonymous white (n=45) and African-American (n=46) individuals. DNA was analyzed, and SNPs were identified using Phred, Phrap, and Consed software. DNA constructs containing MCH-R1 and MCH-R2 SNPs were generated and expressed in CHO cells. The effect of the SNPs in MCH-R1 and MCH-R2 were assessed in receptor binding assays and functional assays measuring changes in intracellular cAMP and Ca2+ levels. RESULTS: We identified 12 SNPs in the MCH-R1 gene. Two of these SNPs are in coding regions, and one produces an arginine-for-glycine substitution at residue 34 in the MCH-R1 sequence. This SNP is present at a minor allele frequency of 15% in the African-American population tested in this study. We identified eight SNPs in the MCH-R2 gene. Four of these SNPs are in coding regions, and two produce amino acid substitutions. Lysine substitutes for arginine at residue 63 of the African-American population, and glutamine substitutes for arginine at residue 152 in whites (minor allele frequency of 2% for both SNPs). No changes in receptor binding or functional signaling were observed with the SNP mutations in MCH-R1 or MCH-R2. DISCUSSION: These data indicate that potential therapeutics designed to act at the MCH receptor are unlikely to have altered effects in subpopulations that express variant forms of MCH-R1 or MCH-R2.


Assuntos
Polimorfismo de Nucleotídeo Único , Receptores do Hormônio Hipofisário/genética , Receptores de Somatostatina/genética , Sequência de Aminoácidos , População Negra , Éxons , Humanos , Hormônios Hipotalâmicos/química , Hormônios Hipotalâmicos/metabolismo , Íntrons , Melaninas/química , Melaninas/metabolismo , Dados de Sequência Molecular , Hormônios Hipofisários/química , Hormônios Hipofisários/metabolismo , Reação em Cadeia da Polimerase , Regiões Promotoras Genéticas/genética , Splicing de RNA , Receptores Acoplados a Proteínas G , Análise de Sequência de DNA , População Branca
12.
BMC Cancer ; 4: 4, 2004 Jan 29.
Artigo em Inglês | MEDLINE | ID: mdl-15005807

RESUMO

BACKGROUND: Carcinogenesis occurs, at least in part, due to the accumulation of mutations in critical genes that control the mechanisms of cell proliferation, differentiation and death. Publicly accessible databases contain millions of expressed sequence tag (EST) and single nucleotide polymorphism (SNP) records, which have the potential to assist in the identification of SNPs overrepresented in tumor tissue. METHODS: An in silico SNP-tumor association study was performed utilizing tissue library and SNP information available in NCBI's dbEST (release 092002) and dbSNP (build 106). RESULTS: A total of 4865 SNPs were identified which were present at higher allele frequencies in tumor compared to normal tissues. A subset of 327 (6.7%) SNPs induce amino acid changes to the protein coding sequences. This approach identified several SNPs which have been previously associated with carcinogenesis, as well as a number of SNPs that now warrant further investigation CONCLUSIONS: This novel in silico approach can assist in prioritization of genes and SNPs in the effort to elucidate the genetic mechanisms underlying the development of cancer.


Assuntos
Bases de Dados Genéticas , Frequência do Gene , Neoplasias/genética , Polimorfismo de Nucleotídeo Único/genética , Etiquetas de Sequências Expressas , National Library of Medicine (U.S.) , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...